Athenex and the center for cell and gene therapy announce allowance of our first u.s. patent claims around car-nkt cell therapy

Patent includes a pharmaceutical composition claim comprising a plurality of genetically modified cd62l-positive human nkt cells comprising at least one chimeric antigen receptor (car)

ATNX Ratings Summary

ATNX Quant Ranking